Psychological factors and obesity, not thyroid biomarkers, predict thyroid-dependent quality of life in treated hypothyroidism: a cross-sectional study.

Thyroid-specific biomarkers had no association with thyroid-dependent quality of life in treated hypothyroid patients.

• Biomarkers tested included TSH, FT3, FT4, rT3, SPINA-GD, anti-TPO, and SHBG.
• Mean TSH was 1.8 ± 0.9 mIU/L, indicating biochemically adequate replacement.
• Neither markers of autoimmune inflammation (anti-TPO) nor markers of tissue-level thyroid hormone action showed significant associations with QoL.
• This finding applied across both univariable and multivariable linear modeling approaches.

The final multivariable model identified somatosensory amplification, BMI, and depression as the factors associated with thyroid-dependent quality of life.

• The final multivariable model had an r² = 0.31, explaining 31% of variance in thyroid-dependent QoL.
• Somatosensory amplification was associated with QoL at p = 0.002.
• BMI was associated with QoL at p = 0.021.
• Depression was associated with QoL at p < 0.001.
• The outcome measure used was the Underactive Thyroid-Dependent Quality of Life Questionnaire (ThyDQoL).

Somatosensory amplification was a strong predictor of the presence and perceived bother of the most common hypothyroidism-associated symptoms.

• Somatosensory amplification was assessed using a validated questionnaire.
• It predicted both the presence and the perceived bother of symptoms commonly attributed to hypothyroidism.
• Somatosensory amplification was identified as the strongest psychological predictor, with mediation analysis used to further characterize its role.
• This finding suggests symptom burden may be substantially influenced by a tendency to amplify somatic sensations rather than by thyroid hormone levels.

The study sample consisted of 157 carefully selected patients with treated primary hypothyroidism, predominantly with Hashimoto's thyroiditis.

• 70.7% had Hashimoto's thyroiditis, whereas 29.3% had iatrogenic hypothyroidism.
• Mean age was 49.5 ± 14.5 years and mean disease duration was 11.2 ± 8.2 years.
• Mean levothyroxine dose was 1.2 µg/kg bodyweight.
• Patients were stringently selected to minimize confounding effects of comorbidities or inadequate hormone replacement.
• Three patient-reported outcome measures were used: somatosensory amplification scale, a depression questionnaire, and a symptom number assessment.

The study findings do not support a significant role for autoimmune inflammation or tissue-level hypothyroidism in determining quality of life in adequately treated patients.

• Anti-TPO antibodies, used as a marker of autoimmune inflammation, showed no association with thyroid-dependent QoL.
• SPINA-GD (a marker of peripheral T3 generation) and rT3 (used to assess tissue-level thyroid hormone availability) were also non-significant.
• The authors concluded that 'these results do not corroborate a significant role for autoimmune inflammation or tissue-level hypothyroidism.'
• Individual variations in thyroxine conversion were assessed via FT3/FT4 ratio and SPINA-GD but were not associated with QoL.